Scientists reported a novel small molecule, Sibiriline, that simultaneously inhibits necroptosis and ferroptosis in preclinical models. The study describes Sibiriline’s biochemical activity against key mediators of both programmed necrotic pathways and shows protective effects in cellular assays of inflammation and degenerative injury. Blocking both pathways with a single agent could open new therapeutic avenues for diseases where overlapping cell‑death modalities drive pathology, although translational steps toward safety and in vivo efficacy remain to be completed.